Riou JF - Search Results

1

Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of taxotere (docetaxel).

Ojima I, Duclos O, Zucco M, Bissery MC, Combeau C, Vrignaud P, Riou JF, Lavelle F. Ojima I, et al. Among authors: riou jf. J Med Chem. 1994 Aug 5;37(16):2602-8. doi: 10.1021/jm00042a013. J Med Chem. 1994. PMID: 7914541

2

Effects of Taxotere on murine and human tumor cell lines.

Riou JF, Naudin A, Lavelle F. Riou JF, et al. Biochem Biophys Res Commun. 1992 Aug 31;187(1):164-70. doi: 10.1016/s0006-291x(05)81474-3. Biochem Biophys Res Commun. 1992. PMID: 1381586

3

Preclinical evaluation of docetaxel (Taxotere).

Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Lavelle F, et al. Among authors: riou jf. Semin Oncol. 1995 Apr;22(2 Suppl 4):3-16. Semin Oncol. 1995. PMID: 7740328 Review.

4

Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series.

Nguyen CH, Lavelle F, Riou JF, Bissery MC, Huel C, Bisagni E. Nguyen CH, et al. Among authors: riou jf. Anticancer Drug Des. 1992 Jun;7(3):235-51. Anticancer Drug Des. 1992. PMID: 1319166

5

Synthesis and biological evaluation of O-alkylated tropolones and related alpha-ketohydroxy derivatives as ribonucleotide reductase inhibitors.

Tamburlin-Thumin I, Crozet MP, Barrière JC, Barreau M, Riou JF, Lavelle F. Tamburlin-Thumin I, et al. Among authors: riou jf. Eur J Med Chem. 2001 Jun;36(6):561-8. doi: 10.1016/s0223-5234(01)01249-1. Eur J Med Chem. 2001. PMID: 11525847

6

Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.

Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, Riou JF, Commerçon A, Lavelle F, Bissery MC. Vrignaud P, et al. Among authors: riou jf. Clin Cancer Res. 2013 Jun 1;19(11):2973-83. doi: 10.1158/1078-0432.CCR-12-3146. Epub 2013 Apr 15. Clin Cancer Res. 2013. PMID: 23589177

7

Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.

Riou JF, Fossé P, Nguyen CH, Larsen AK, Bissery MC, Grondard L, Saucier JM, Bisagni E, Lavelle F. Riou JF, et al. Cancer Res. 1993 Dec 15;53(24):5987-93. Cancer Res. 1993. PMID: 8261412

8

Preclinical evaluation of CPT-11 and its active metabolite SN-38.

Lavelle F, Bissery MC, André S, Roquet F, Riou JF. Lavelle F, et al. Among authors: riou jf. Semin Oncol. 1996 Feb;23(1 Suppl 3):11-20. Semin Oncol. 1996. PMID: 8633248 Review.

9

Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.

Nguyen CH, Fan E, Riou JF, Bissery MC, Vrignaud P, Lavelle F, Bisagni E. Nguyen CH, et al. Among authors: riou jf. Anticancer Drug Des. 1995 Jun;10(4):277-97. Anticancer Drug Des. 1995. PMID: 7786395

10

Multivariate data analysis using D-optimal designs, partial least squares, and response surface modeling: A directional approach for the analysis of farnesyltransferase inhibitors.

Giraud E, Luttmann C, Lavelle F, Riou JF, Mailliet P, Laoui A. Giraud E, et al. Among authors: riou jf. J Med Chem. 2000 May 4;43(9):1807-16. doi: 10.1021/jm991166h. J Med Chem. 2000. PMID: 10794697

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters